Ardsley Advisory Partners’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Ardsley Advisory Partners’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-194	Closed	-$89K	–	152
2018 Q4	$89K	Hold	194	–	–	0.02%	96
2018 Q3	$177K	Buy	+194	New	+$128K	0.02%	141

Other funds holding HTGM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Ardsley Advisory Partners's HTGM Position: Q1 2019 in Review

Ardsley Advisory Partners sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q1 2019, closing a stake of 194 shares — an estimated $89K sold.

Ardsley Advisory Partners first reported a position in HTGM in Q3 2018 and held it in 2 quarters. The position peaked at $177K in Q3 2018. 39 funds tracked by Wall St. Rank hold HTGM as of Q1 2019.

Ardsley Advisory Partners reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Ardsley Advisory Partners sold 194 HTG Molecular Diagnostics, Inc. Common Stock shares in Q1 2019, an estimated $89K.
Ardsley Advisory Partners first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q3 2018 and held it in 2 quarters.
Ardsley Advisory Partners's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $177K in Q3 2018.
39 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q1 2019.

Based on Ardsley Advisory Partners's 13F filing for Q1 2019, filed 15 May 2019.